More on Celgene Q1 results


Net product sales increased 19% yoy to $1.71B. Net income was $280M (-27.3%) or $0.66/share (-25.8%).

Revlimid sales increased 14% to $1.14B. U.S. revenue was $642M (+13%) and International was $502M (+16%).

Abraxane sales were $185M (+51%).

Vidaza sales were $148M (-27%).

Pomalyst/Imnovid sales were $136M.

10.7M shares were repurchased for a total cost of ~$1.7B. As of March 31 there was $407M remaining to be repurchased under the program. On April 17, the BOD authorized an additional $4B.

CF Ops was $557M (+51.6%).

Updated 2014 guidance includes total revenues of $7.5B, Revlimid sales of $4.9B - $5B, Abraxane sales of $850M - $900M and EPS of $4.94 - $5.18.

(CELG)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs